JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Low-Density Lipoprotein (LDL) is Associated with Earlier Progression in Synchronous Metastatic Colorectal Cancer Treated without Curative Intent

  • 0Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, Türkiye.
Journal of Gastrointestinal Cancer +

|

February 5, 2025

|

February 5, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

High LDL cholesterol levels (>130 mg/dL) in metastatic colorectal cancer (CRC) patients correlate with colonic primary tumors. While not impacting survival with curative treatment, high LDL is linked to worse progression-free survival without curative intent.

Area Of Science

  • Oncology
  • Metabolic Syndrome
  • Gastroenterology

Background

  • Low-density lipoprotein cholesterol (LDL) is implicated in colorectal cancer (CRC) development.
  • The prognostic significance of LDL in metastatic CRC remains to be fully elucidated.

Purpose Of The Study

  • To investigate the prognostic role of serum LDL levels in patients with synchronous metastatic CRC.
  • To identify clinicopathological factors associated with LDL levels in this patient cohort.

Main Methods

  • Patients with newly diagnosed synchronous metastatic CRC were stratified into Normal-LDL (≤130 mg/dL) and High-LDL (>130 mg/dL) groups.
  • Clinicopathological factors, progression-free survival (PFS), and overall survival (OS) were analyzed.
  • Treatment strategies, including local treatments and those with curative intent, were assessed.

Main Results

  • Higher LDL levels were associated with a higher frequency of colonic primary tumor localization (90% vs. 67.5%, p=0.009).
  • The High-LDL group received more local treatments (metastasectomy, embolization-ablation) despite similar PFS and OS compared to the Normal-LDL group.
  • Among patients not treated with curative intent, High-LDL was significantly associated with worse PFS (4.97 months vs. 8.43 months, p=0.048).

Conclusions

  • Serum LDL levels may be associated with colonic primary tumor site in metastatic CRC.
  • LDL levels >130 mg/dL could serve as a potential prognostic biomarker, particularly in patients without curative treatment intent.
  • Further large-scale, multicenter, prospective studies are warranted to validate these findings.

Keywords:

Related Concept Videos

Metastasis 02:30

5.5K

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

Tumor Progression 02:07

6.2K

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Targeted Cancer Therapies 02:57

7.4K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...